Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03938246 · ClinicalTrials.gov registry record · Phase 2
Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 study, sponsored by Sagimet Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
NCT03938246: Completed Phase 2 study, sponsored by Sagimet Biosciences.
NCT03938246 is a Phase 2 study that has completed, run by Sagimet Biosciences. The registered enrollment target is 142 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03938246, a Phase 2 study, has completed, sponsored by Sagimet Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
Study Summary
This is a Phase 2 multi-center, randomized, single-blind, placebo-controlled study to evaluate the safety and efficacy of TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. Subjects will be randomly assigned to 1 of 2 treatment groups (TVB-2640 at one of three doses or placebo). Following randomization, subjects will begin the 12-week treatment period and will receive once daily TVB-2640 or placebo.
Primary Outcome
As determined by MRI-PDFF
Interventions
- DRUG TVB-2640 25 mg (US)
- DRUG TVB-2640 50 mg (US)
- DRUG Placebo (US)
- DRUG TVB-2640 50 mg (China)
- DRUG Placebo (China)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2019-03-22 |
| Est. Completion | 2021-10-02 |
| Phase | Phase 2 |
What the finished NCT03938246 record still lists
NCT03938246 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which TVB-2640 25 mg (US) is the first listed.
NCT03938246 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03938246 about?
NCT03938246 is a clinical study titled "Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)". This is a Phase 2 multi-center, randomized, single-blind, placebo-controlled study to evaluate the safety and efficacy of TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. Subjects will be randomly assigned to 1 of 2 treatment groups (TVB-2640 at one of t...
What is the current status of trial NCT03938246?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2019-03-22. Estimated completion is 2021-10-02.
What interventions are being tested in trial NCT03938246?
The interventions under investigation include: TVB-2640 25 mg (US) (DRUG), TVB-2640 50 mg (US) (DRUG), Placebo (US) (DRUG), TVB-2640 50 mg (China) (DRUG), Placebo (China) (DRUG).
Who is sponsoring clinical trial NCT03938246?
This trial is sponsored by Sagimet Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03938246's enrollment target sits among peer trials
142 507th of 2000 higher than 1,491 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI